Nivolumab was the first immune checkpoint inhibitor approved for previously treated advanced non-small cell lung cancer (NSCLC). Before its introduction in the market, nivolumab was made available to NSCLC patients through an expanded access program (EAP). Here we present the Italian cohort of patients with non-squamous NSCLC enrolled in a worldwide nivolumab EAP, with subgroup analyses involving elderly patients, patients with central nervous system (CNS) metastases and patients receiving nivolumab beyond progression.
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer / Grossi, F.; Genova, C.; Crino, L.; Delmonte, A.; Turci, D.; Signorelli, D.; Passaro, A.; Soto Parra, H.; Catino, A.; Landi, L.; Gelsomino, F.; Tiseo, M.; Puppo, G.; Roila, F.; Ricciardi, S.; Tonini, G.; Cognetti, F.; Toschi, L.; Tassinari, D.; Scoppola, A.; Giannarelli, D.; Cortesi, E.. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 123:(2019), pp. 72-80. [10.1016/j.ejca.2019.09.011]
Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non–small cell lung cancer
Tiseo M.;
2019-01-01
Abstract
Nivolumab was the first immune checkpoint inhibitor approved for previously treated advanced non-small cell lung cancer (NSCLC). Before its introduction in the market, nivolumab was made available to NSCLC patients through an expanded access program (EAP). Here we present the Italian cohort of patients with non-squamous NSCLC enrolled in a worldwide nivolumab EAP, with subgroup analyses involving elderly patients, patients with central nervous system (CNS) metastases and patients receiving nivolumab beyond progression.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
